Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Gavi Fund To Guarantee Global Market For COVID-19 Vaccines

Aim Is To Incentivize Investment And Ensure Equitable Access

Executive Summary

The latest global vaccines summit has seen the launch of a new mechanism designed to spur the development of new coronavirus vaccines and ensure they are made available, particularly in low- and middle-income countries.

You may also be interested in...



Coronavirus Notebook: Vaccine Pooling, WHO’s Law Lab & The Role Of The Llama

The coronavirus research field may be dominated by vaccines from the likes of Oxford University/AstraZeneca and Pfizer/BioNTech, but a lot of interesting work is being done elsewhere by smaller academic and commercial projects looking at the potential of various novel antibody therapies against COVID-19. 

Coronavirus Notebook: Gavi Vaccines Move Under Fire, EU-US Step Up Regulatory Cooperation

In this latest Coronavirus Notebook, an international vaccine incentive mechanism comes under attack, researchers look at how to solve cold-chain coronavirus distribution problems in Africa, and Sanofi invests in a “world reference” vaccines R&D facility. 

COVID-19 Vaccine Manufacturing: Moderna CEO Worries Most About Raw Materials

Moderna's Bencal and Merck Vaccine head Markels discuss the difficulties in scaling up manufacturing capacity for vaccine candidates at BIO plenary session; CEPI CEO says his organization can help facilitate pairing of vaccine development partners.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142321

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel